For patients with advanced cancer, medical costs have continued to rise as the disease progresses, often without meaningful clinical benefit.
Solid tumors accompanied by peritoneal metastasis are difficult to treat and show high recurrence rates, and conventional systemic chemotherapy—whether used alone or in combination—has shown limited effectiveness.

DREAMPAC is developing technologies that provide meaningful treatment options for patients with advanced cancer, with the goal of extending survival and improving quality of life.

PIPAC, which is being introduced clinically in Europe, faces technical limitations and remains uncertain for domestic adoption.
In response, DREAMPAC has developed RIPAC, an advanced approach beyond PIPAC, and has introduced it domestically.

DREAMPAC aims to deliver RIPAC as a new medical solution that improves survival outcomes and quality of life for patients with advanced cancer.